If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
230
results.
Updated on
24/12/2025 [06:58:00]
Results 75 to 100 of 230
Absstract of: US2025381228A1
Disclosed herein are methods for treating osteoarthritis may be a one-step arthroscopic procedure and may include detaching synovial mesenchymal stem cells (MSCs) from the synovium using a brush device: covering articular cartilage in an affected joint with a scaffold, and placing concentrated MSC exosomes into the affected joint to stimulate differentiation of synovial MSCs into articular cartilage cells.
Absstract of: US2025381150A1
Provided are lipid nanoparticles, compositions, and methods of making and using the same. The lipid nanoparticles contain ionizable lipids, structural lipids, PEG lipids and specific amounts of helper lipids. The lipid nanoparticles may further contain a cell targeting group coupled to a PEG lipid. The lipid nanoparticles may carry a cargo, e g., a mRNA. The lipid nanoparticles may be used for transfection of cells, e.g., immune cells or hematopoietic stem cells.
Absstract of: US2025381139A1
A multi-tail type ionizable lipid, a preparation method therefor and the use thereof are disclosed. The structural formula of the multi-tail type ionizable lipid of the present invention is as follows,wherein R1 and R2 are the same or different, and each is hydrogen or an alkyl chain or an alkyl ring consisting of 1 to 6 carbons, or R1 and R2 together form a nitrogen-containing alkyl ring; L1 and L2 are the same or different, and each is an alkyl chain or an unsaturated hydrocarbyl group consisting of 1 to 6 carbons in length; and R is an alkyl group, an alkyl ring, an unsaturated hydrocarbyl group, or a heterohydrocarbyl group; and n=1 to 6, m1=1 to 15, m2=1 to 15, and x=0 to 5.
Absstract of: US2025381138A1
The present nanoemulsions are a delivery system for virtually any non-opioid active agent for pain, and contain: a hydrocarbon lipid; a perfluorocarbon; water and/or buffered saline; a nonionic surfactant; and optionally a quaternary ammonium compound and/or an additional lipid. Droplets of the non-opioid analgesic formulations have a diameter of 150 nm or less, and preferably range from 90 nm to about 120 nm and have shelf stability for at least twelve months. The nanoemulsions are suitable for a wide variety of routes of administration, including but not limited to IV and parenteral, the latter having particular battlefield and war zone suitability.
Absstract of: WO2024168133A1
Disclosed are compounds, nanoparticles, and compositions for effective delivery of metabolic inhibitors to disease state cells. The compounds, nanoparticles, and compositions disclosed herein show trackability in biological system, extended stability, and other adventageous physicochemical properties to treat various disease states. Also disclosed are methods of treating a subject in need thereof, such as a subject with cancer.
Absstract of: AU2024217077A1
The present disclosure relates to lipid nanoparticles including a lipid layer, a cell-penetrating peptide conjugated to the lipid layer, a collagen-targeting peptide conjugated to the lipid layer and a nucleic acid associated with a vascular disease or condition. The present disclosure also relates to methods of making and using the described lipid nanoparticles for treating vascular disease.
Absstract of: EP4663208A1
The present invention relates to polysaccharide-crosslinked colloidal particles and their use as modifiers for substances intended for in vivo administration.The present invention provides a polysaccharide-crosslinked colloidal particle platform that is not only capable of serving as a drug delivery vehicle for functional nanoparticles or drugs intended for in vivo administration, but also can be engineered to regulate in vivo biodistribution and excretion.
Absstract of: EP4663207A1
The present invention relates to a formulation for non-intravenous administration, comprising nanoparticles having a hydrodynamic diameter of 2 to 20 nm and a surface charge ranging from -20 mV to 0 mV, the nanoparticles being adjusted in size and charge by hydration of hydrophilic functional groups exposed on the surface thereof, such that the nanoparticles are not permeated into or drained into blood capillaries at the administration site but are selectively drained into terminal lymphatic vessels, wherein the nanoparticles: (i) are themselves therapeutic agents; and/or (ii) serve as carriers for other therapeutic agents, and wherein the nanoparticles are engineered to provide a drug modality that, upon administration into a tissue site rather than via intravenous injection, is selectively drained into lymphatic vessels, thereby avoiding drainage into blood capillaries and thus prolonging residence time at the administration site.According to the present invention, the nanoparticles with the adjusted hydrodynamic diameter and surface charge are configured to be completely cleared from the administration site within one week after administration without residual accumulation. When designed as a T1 MRI contrast agent, the nanoparticles enable selective imaging of peripheral and/or central lymphatic vessels without venous contamination when administered to perivascular tissue.
Absstract of: TW202506200A
The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.
Absstract of: EP4663206A1
The present invention relates to a next-generation antibody-drug conjugate (ADC) linker platform technology and to polysaccharide-crosslinked colloidal particle-drug conjugates.More specifically, the invention is characterized by the use of polysaccharide-crosslinked colloidal particles-formed by intramolecular and/or intermolecular crosslinking of 1 to 3 branched polysaccharides or 2 to 30 cyclic polysaccharides at hydroxyl groups of their monosaccharide building blocks using a crosslinker-as a multivalent linker system or drug carrier. For example, the invention includes dextran-crosslinked nanoparticles (CDex), which are formed by intramolecular and/or intermolecular crosslinking of 1 to 3 dextran or dextran derivatives at the hydroxyl groups of glucose building blocks using a crosslinker.
Absstract of: EP4663205A1
A nano-size controllable and stable polymer-drug conjugate, an intermediate thereof, and a use thereof. Provided is a polymer-drug conjugate as represented by formula (I) and having different polymer bodies, a controllable coupled group quantity, controllable group coupling sites and a controllable nano-size. The drug conjugate has one or more of the following advantages: a low renal clearance rate, a low liver-spleen clearance rate, long plasma half-life, strong drug accumulation capability at lesion tissues, strong drug permeability at lesion tissues, low toxic and side effects, and an excellent treatment effect.
Absstract of: EP4663624A1
Provided in the present disclosure is a compound of formula (I), or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, which is an extrahepatic targeted cationic lipid compound with high efficiency and low toxicity. Further provided are a composition containing the aforementioned compound, and the use thereof in the delivery of a therapeutic or prophylactic agent.
Absstract of: WO2024165949A1
The present invention relates to a method for the production of gold nanoparticles (AuNPs) coated with glutathione and Li+ ions, hereinafter designated as LiG-AuNPs, to a method for the preparation of aggregates of said nanoparticles and to the use of said nanoparticles, aggregates or compositions thereof which comprise them for therapeutic use. LiG-AuNPs then are an effective instrument in inhibiting GSK-3 and its downstream molecular targets, while keeping the lithium extracellular concentration levels below the systemic toxicity threshold (1.5 mEq/L), and exerting an antioxidant action by means of the glutathione present on their surface.
Absstract of: WO2024165567A1
The present invention relates to anti-mesothelin constructs, such as antigen binding fragments and single-domain antibodies, that specifically bind to mesothelin, irrespective of the presence of MUC16. The invention further relates to the use of anti-mesothelin constructs in diagnostics and in therapeutic field.
Absstract of: WO2024165565A1
The present invention relates to a composition comprising lipid nanoparticles comprising rosehip oil, at least one solid lipid, at least one surfactant, and optionally at least one active ingredient, as well as their use in a method of treating ocular diseases, such as for example dry eye disease.
Absstract of: EP4663243A2
The present invention relates to a freeze-dried (also called lyophilized) drug nanosuspension. The present freeze-dried drug nanosuspension composition has an acceptable stability of the particle size distribution during storage, including long term storage.
Absstract of: MX2025009357A
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
Absstract of: AU2024251515A1
The present application relates to lipid nanoparticles containing a steroid compound, and the preparation and a use of the lipid nanoparticles. The lipid nanoparticles can be used to deliver effective loads (such as a nucleic acid) into non-liver organs such as the spleen for the treatment or prevention of certain diseases or conditions, particularly spleen-associated diseases.
Absstract of: AU2023425729A1
A method of targeting antigen-presenting cells and delivering an encapsulated payload with lipid nanoparticles including a POZ-lipid conjugate. The encapsulated payload may include, but is not limited to, a nucleic acid payload such as mRNA or modified mRNA. These LNPs are not subject to accelerated blood clearance and they have a low or reduced immunogenicity profile in vivo.
Absstract of: MX2025006274A
This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.
Absstract of: CN120641080A
Compositions and methods for the control and treatment of obesity, metabolic disorders, nausea and vomiting using ODN peptides and synthetic derivatives thereof are disclosed.
Absstract of: CN120225500A
The present invention relates to a novel lipid compound, and a lipid nano particle (LNP) composition comprising the same, and more particularly, to a lipid nano particle (LNP) composition comprising the same. The lipid compound according to the present invention can directly or indirectly bind to an active substance through multivalent interaction and surround the active substance, thereby increasing the structural stability of the active substance. Moreover, the lipid nanoparticles comprising the lipid compound can significantly improve the delivery efficiency and activity of an active substance into cells, and thus can be used for the treatment and prevention of diseases.
Absstract of: CN120769741A
Provided herein are compositions for genetic modification associated with a base editor system, and methods of using the compositions to treat or prevent conditions associated with extracellular deposition of amyloid fibrils formed by aggregation of misfolded thyroxine transporter (TTR) proteins in various tissues. Such conditions include, but are not limited to: polyneuropathy caused by hereditary thyroxine transporter amyloidosis (hATTR-PN) and hereditary cardiomyopathy caused by thyroxine transporter amyloidosis (hATTR-CM), both of which are associated with autosomal dominant mutation of the TTR gene; and age-related cardiomyopathy (ATTRwt) associated with the wild-type TTR protein, also referred to as senile cardiac amyloidosis.
Absstract of: CN121129819A
本发明属于医学技术领域，具体涉及一种酯酶响应性异羟肟酸类HDAC抑制剂二聚体前药、自组装纳米颗粒及其应用。本发明将酯酶响应性连接臂引入形成HDACi二聚体前药，再通过自组装形成纳米颗粒，构建了兼具静脉可注射性和智能释药特性的纳米递送平台，克服游离HDACi因水溶性差无法静脉给药、体内清除快及脱靶毒性高的临床应用瓶颈。
Nº publicación: CN121129814A 16/12/2025
Applicant:
康道生物（南通）有限公司
Absstract of: CN121129814A
本发明涉及医药与功能性食品技术领域，具体为一种基于胶原蛋白肽和蛋壳膜肽自组装的姜黄素纳米复合物及其制备方法，纳米复合物由以下组分按质量百分比组成：蛋壳膜肽40%‑60%、I型胶原蛋白肽25%‑40%、II型胶原蛋白肽10%‑20%、姜黄素10%‑20%，所述纳米复合物为核‑壳结构纳米胶束，制备方法包括原料预处理、配制有机溶剂、溶解疏水组分、旋转蒸发成膜、配制亲水肽溶液、水化自组装、纯化处理；本发明可改善姜黄素溶解度与稳定性，提升口服生物利用度；载体为天然肽类，安全且具生物活性，适配医药制剂与功能性食品需求，产业化潜力高。
BOPI
Electronic site
